In particular, CV9202 encoding six tumor-associated antigens(NY-ESO-1, MAGE-C1, MAGE-C2, Survivin, 5T4 and MUC) demonstrated good tolerance and elicited antigen-specific immune responses in a phase Ib study of stage IV NSCLC patients (339). The gene discussed is MAGEC1; the disease is non-small cell lung carcinoma.